Conference

American Association for Cancer Research (AACR) Annual Meeting

Meet with Q2 Solutions at AACR 2018, booth #2415 and learn how we can partner with you in your cancer research and clinical development programs

Chicago, IL | April 14, 2018 - April 18, 2018 | 08:00 - 17:00 Add to Calendar
Register for presentation post-event Schedule a Meeting

About This Event

From biomarkers, companion diagnostics, esoteric testing, high quality data, bioinformatics and analytics, to robust logistics and sample management, Q2 Solutions’ industry leading lab services are closely tailored to power your oncology study every step of the way.

Our range of genomic services and dedicated team can help you uncover invaluable insights from your data and design smarter studies, leveraging latest cancer research and precision medicine findings. Through carefully orchestrated analyses, we work with you to choose platforms and assays that will distinctly fit your needs, and then use them to deliver quality informative data and breakthrough genomic know-how®.

Through Q2 Solutions’ Oncology Center of Excellence, our experts in biomarker discovery are providing a better understanding of therapeutic targets, molecular signaling, drug biology and patient response to accelerate your cancer research and clinical outcomes.

Be sure to stop by our 8 poster presentations during the AACR to gain insights within molecular diagnostics, application of bioinformatics to cancer biology, high-throughput sequencing, new software for data analysis, and tumor biology. Please find details around each poster presentation as follows:

  1. Title: TMB effects of sequencing parameters and panel size on mutational burden calculations
    Abstract: LB-381
    Date and Time: Wednesday, April 16, 8:00 am-12:00 pm
    Location: McCormick Place South, Exhibit Hall A, Poster Section 45
    Poster Board #: 9   
    Author: Victor Weigman, Director, Translational Genomics

  2. Title"TMB calling in absence of matched normal: Learning germline behavior"  
    Abstract: LB-380
    Date and Time: Wednesday April 18, 2018, 8:00 am-12:00 pm
    Location: McCormick Place South, Exhibit Hall A, Poster Section 45   
    Poster Board #: 8   
    Author: Natalie Mola, Bioinformatician, Translational Genomics

  3. Title: Tumor Mutational Burden: Guidelines for derivation and robustness of measurement
    Abstract: 2250
    Date and Time: Monday, April 16, 2018, 1:00 pm - 5:00 pm
    Location: McCormick Place South, Exhibit Hall A, Poster Section 12
    Poster Board #: 7
    Author: Natalie Mola, Bioinformatician, Translational Genomics

  4. Title: Optimization of an RNA sequencing method for low-quantity degraded samples
    Abstract: 429
    Date and Time: Sunday April 15, 2018, 1:00 pm-5:00 pm
    Location: McCormick Place South, Exhibit Hall A, Poster Section 19
    Poster Board #: 14
    Author: Dan Su, Translational R&D

  5. Title: Immune microenvironment characteristics of primary tumor predict long-term disease-free survival in high-grade serous ovarian cancer (HGSOC)”
    Abstract: 4050
    Date and Time: Tuesday April 17, 2018, 1:00 pm- 5:00 pm
    Location: McCormick Place South, Exhibit Hall A, Poster Section 3
    Poster Board #:  8
    Author: Wendell Jones, Principal Bioinformaticist and Scientific Advisor

  6. Title: Effect of tumor purity on somatic mutation detection using next generation sequencing technology: A benchmarking study
    Abstract: 1307
    Date and Time: Monday April 16, 2018, 8:00 am - 12:00 pm   
    Location: McCormick Place South, Exhibit Hall A, Poster Section 12
    Poster Board #: 30   
    Author: Wendell Jones, Principal Bioinformaticist and Scientific Advisor

  7. Title: “Sensitive Detection of MET Exon 14 Skipping by RT-qPCR and Next Generation Sequencing
    Abstract: 1626
    Date and Time: Monday April 16, 2018 8:00 am - 12:00 pm   
    Location: McCormick Place South, Exhibit Hall A, Poster Section 27
    Poster Board #: 27
    Author: Mukund Patel, Manager, Translational Genomics   

  8. Title: STAR-SEQR: Accurate fusion detection and support for fusion neoantigen applications"
    Abstract: 2296
    Date and Time: Monday April 16, 2018, 1:00 pm- 5:00 pm   
    Location: McCormick Place South, Exhibit Hall A, Poster Section 13
    Poster Board #: 23
    Author: Victor Weigman, Director, Translational Genomics

Schedule a meeting with Q2 Solutions at this year’s AACR, booth #2415, to learn how through our deep scientific expertise and industry-leading technology, we can partner with you in effectively harnessing the latest wave of progress against cancer.

We look forward to meeting you in Chicago.

Related Services:

Register for Event

Speakers

Victor Weigman, Ph.D.
Director, Translational Genomics

Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.

Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays.  Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.

Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.

Updated as of September 2018.

Wendell Jones, Ph.D.
Bioinformatics

Dr. Jones is currently Principal Bioinformaticist and Scientific Advisor at Q2 Solutions | EA Genomics. He conducts collaborative scientific research with clients in multiple areas, especially in oncology and immuno-oncology. His background includes leading the analysis, development and validation of the bioinformatic and computational systems that process complex genomic assays, including next generation sequencing assays, evaluating new and emerging genomic technologies, and developing bioinformatic implementation strategies. He consults with clients and provides thought leadership in industry and public consortiums involved in genomic science and measurement. Dr. Jones serves on the Board of Directors as Vice President of the new MAQC Society andis currently participating in the U.S. Food and Drug Administration (FDA)-led Sequencing Quality Control 2 (SEQC2) consortium which is investigating best-practice methods for variant calling in DNA sequencing studies.  Dr. Jones previously had leadership roles in the MAQC, MAQC-II, and SEQC consortiums.

Dr. Jones has over 15 years of experience in advanced genomic technologies and 20 years of experience in scientific and technology leadership positions, including serving as Vice President of Statistics and Bioinformatics at Expression Analysis, Inc (EA) and Chief Science Officer at Reliametrics, a Nortel Networks business unit. He has authored over 40 peer-reviewed publications and has presented at numerous scientific meetings and industry conferences and consortium workshops. Dr. Jones also serves as Adjunct Assistant Professor in the School of Medicine (Dept. of Pathology and Laboratory Medicine) at the University of North Carolina at Chapel Hill.

Updated as of September 2018.

Companion Diagnostic Expertise

Learn how we can ensure success in your next companion diagnostic development program

Precision medicine: Shifting from one drug for all patients to personalized genomics-based therapeutic options

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Read More